Pharmabalance
ActiveFinancials · financial year 2025, micro format
Annual accounts 2025 filed on 10-02-2026 at the NBB
Amounts without an identifiable currency are taken as euros.
Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Subsidies and aid
Flemish government
2025 · 1 entry · €30 awarded · €30 paid| Line | 2025 |
|---|---|
| Other operating charges640/8 | €427 |
| Gross operating margin9900 | €65,014 |
| Operating profit (loss)9901 | €64,587 |
| Financial charges65/66B | €79 |
| Recurring financial charges65 | €79 |
| Profit (loss) for the period before taxes9903 | €64,508 |
| Income taxes67/77 | €13,492 |
| Profit (loss) for the period9904 | €51,016 |
| Profit (loss) for the period to be appropriated9905 | €51,016 |
| Line | 2025 | |
|---|---|---|
| Assets | ||
| Total assets20/58 | €75,889 | |
| Current assets29/58 | €75,889 | |
| Amounts receivable within one year40/41 | €12,993 | |
| Trade receivables40 | €12,993 | |
| Cash at bank and in hand54/58 | €62,369 | |
| Deferred charges and accrued income490/1 | €528 | |
| Equity and liabilities | ||
| Total equity and liabilities10/49 | €75,889 | |
| Equity10/15 | €54,183 | |
| Contributions10/11 | €4,000 | |
| Reserves13 | €50,000 | |
| Distributable reserves133 | €50,000 | |
| Profit (loss) carried forward14 | €183 | |
| Amounts payable17/49 | €21,706 | |
| Amounts payable within one year42/48 | €21,706 | |
| Trade debts44 | €28 | |
| Suppliers440/4 | €28 | |
| Taxes, remuneration and social security45 | €20,462 | |
| Taxes450/3 | €20,462 | |
| Other amounts payable47/48 | €1,217 | |
| Line | 2025 |
|---|---|
| Profit (loss) for the period9904 | €51,016 |
| Operating cash flow (approximation) | €51,016 |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 11,279 companies had the same profile as Pharmabalance has now. Two years later, 0.7% had gone bankrupt and 96.6% were still going.
- Micro
- under 2 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
That fits the bankruptcy probability of Pharmabalance itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 11,279 companies, not a prediction for Pharmabalance. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Filings with the National Bank (1)
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | micro format | 10-02-2026 | 2026-00036857 |